C4 Therapeutics, Inc. (CCCC)

NMS – Real vaqt narxi. Valyuta: USD

3.17

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.19

+0.02 (0.53%)

Bozor oldidan: May 13, 2026, 8:24 AM EDT

12.05.2026

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.37 per share a year ago.

12.05.2026

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the first quarter ended March 31, 2026, as well as recent business highlights.

09.04.2026

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of ‌a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.

09.04.2026

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted Antibodies C4T to Receive $20 Million Upfront Payment and Eligible to Receive Over $1 Billion in Discovery, Development and Commercial Milestones, in Addition to Future Royalties WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.

27.03.2026

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

$C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma$

25.03.2026

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy

10.03.2026

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

09.04.2026

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma$

25.03.2026

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy

09.03.2026

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on March 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

C4 Therapeutics, Inc. (CCCC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

C4 Therapeutics, Inc. (CCCC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Videolar

No Data

Press-relizlar

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)